← Back to Search

Behavioural Intervention

EHR Alerts for Heart Failure (BETTER CARE-HF Trial)

N/A
Waitlist Available
Led By Amrita Mukhopadhyay
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient ages 18-90
Be older than 18 years old
Must not have
Hospice
Medication-specific exclusion for MRA: most recent systolic blood pressure less than 105 mm Hg, most recent potassium < 5.1, any potassium > 5.5, most recent glomerular filtration rate < 30 (using MDRD equation), or a documented MRA allergy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to month 36
Awards & highlights

Summary

This trial will test a computerized alert system in electronic health records to help doctors prescribe the right medications for patients with heart failure. The alert has already been used successfully at NYU Langone Health and

Who is the study for?
This trial is for patients with heart failure and reduced ejection fraction (HFrEF). It's designed to test if an electronic alert can help doctors follow heart failure treatment guidelines better. Details on specific inclusion or exclusion criteria are not provided.
What is being tested?
The study is testing an automated alert embedded in the electronic health record system. The goal is to see if it improves the prescription of recommended treatments for HFrEF across multiple health systems.
What are the potential side effects?
Since this trial involves a non-invasive, electronic tool rather than medication, traditional side effects are not applicable. However, there may be indirect impacts on patient care that will be monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 90 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not enrolled in hospice care.
Select...
My blood pressure is above 105, potassium levels are stable, kidney function is adequate, and I'm not allergic to MRAs.
Select...
I have been diagnosed with cardiac amyloidosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to month 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to month 36 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Patients with a Prescription for Mineralocorticoid Antagonists (MRA)
Secondary outcome measures
Number of Patients who are Hospitalized
Number of Patients who are Hospitalized for Heart Failure (HF)
Number of Patients with Hyperkalemia
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Participants who are randomized to receive the intervention (i.e., displaying the automated EHR-embedded alert).
Group II: Standard of CareActive Control1 Intervention
Participants who are randomized to the control group (i.e., not displaying the automated EHR-embedded alert).

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,379 Previous Clinical Trials
845,118 Total Patients Enrolled
16 Trials studying Heart Failure
12,978 Patients Enrolled for Heart Failure
Massachusetts General HospitalOTHER
2,955 Previous Clinical Trials
13,209,678 Total Patients Enrolled
49 Trials studying Heart Failure
209,655 Patients Enrolled for Heart Failure
University of PennsylvaniaOTHER
2,027 Previous Clinical Trials
42,882,711 Total Patients Enrolled
43 Trials studying Heart Failure
7,514 Patients Enrolled for Heart Failure
~0 spots leftby Oct 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top